You just read:

ARCALYST® (rilonacept) Meets Primary and All Secondary Endpoints in Phase 3 Trial of Prevention of Gout Flares in Patients Initiating Allopurinol Therapy

News provided by

Regeneron Pharmaceuticals, Inc.

Jun 09, 2010, 06:55 ET